- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Keryx: Another Beneficiary of the ASCO Effect
-
Two Potential Mega Biotech Deals Fuel Industry Hopes
-
Friday Options Recap
-
Thursday Options Update: SVNT, WFC, EEM, MCO, XHB, EXEL, GDX, HIG
-
Top Biotech Picks for ASCO 2009 (Part II)
-
Top Biotech Picks for ASCO 2009 (Part I)
-
Exelixis Suggests Creativity in Finding Cash for Biotechs in Rough Times
-
Micromet: More Reasons for Optimism
-
9 Possible Pharma Deals for 2009
-
40 Top Rated Emerging Bio-Pharma Stocks
-
Immunogen and Exelixis Defy the Recession
-
Bristol-Myers' Collaboration with Exelixis Is Looking Lucrative
-
Buying More Exelixis in the Post - GlaxoSmithKline Era
-
'When There's Blood in the Streets', Buy Biotech Stocks
-
Licensing Deal Is Imminent for ArQule
-
Exelixis: A Platform Company for Oncology
-
Poniard Pharmaceuticals: Platinum Rediscovered (Part II)
-
Cancer Stocks: Tracking the Market
-
Cancer Stocks: The Bleeding Slows
-
Cancer Stocks Hammered Once Again
-
Cancer Stocks Slide Again
-
Cancer Stocks Plunge Following ASCO Meeting
-
Four Cheap Biotech Stock Picks: Amgen, Aspreva, Exelixis, PDL Biopharma
-
Four Conviction Buys for Our Age of Uncertainty
-
Biotech In Review: Adams Respiratory Guides Lower
-
Biotech Stocks Day In Review: Alfacell Receives Orphan Drug Status For Onconase
-
Report From JPMorgan's HealthCare Conference: The Spinal Business Is Hot
-
Biotech Stocks Day-in-Review: Amgen Strikes Drug Deal With Cytokinetics
-
Exelixis' Special Purpose Entities A Far Cry From Enron (EXEL)
-
Exelixis Upgraded With Good Reason (EXEL)
-
Waiting For More Good News From Exelixis (EXEL)
-
Stocks Covered by The Biotech Stock Blog
-
How Exelixis Excels (EXEL)
-
Exelixis Continues Its Wild Ride (EXEL)